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Deletions in CWH43 cause idiopathic normal
pressure hydrocephalus
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Shuo Zhang1, Yan Ma1, Marciana F Johnson2,3, Anna K Rattray2,3, Tatyana A Johnson2,3,
George Wang1,2,3, Shaokuan Zheng1, Rona S Carroll1,2,3, Peter J Park2,3 & Mark D Johnson1,2,3,4,*
Abstract
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological
disorder that occurs in about 1% of individuals over age 60 and is
characterized by enlarged cerebral ventricles, gait difficulty, incon-
tinence, and cognitive decline. The cause and pathophysiology of
iNPH are largely unknown. We performed whole exome sequencing
of DNA obtained from 53 unrelated iNPH patients. Two recurrent
heterozygous loss of function deletions in CWH43 were observed
in 15% of iNPH patients and were significantly enriched 6.6-fold
and 2.7-fold, respectively, when compared to the general popula-
tion. Cwh43 modifies the lipid anchor of glycosylphosphatidylinosi-
tol-anchored proteins. Mice heterozygous for CWH43 deletion
appeared grossly normal but displayed hydrocephalus, gait and
balance abnormalities, decreased numbers of ependymal cilia, and
decreased localization of glycosylphosphatidylinositol-anchored
proteins to the apical surfaces of choroid plexus and ependymal
cells. Our findings provide novel mechanistic insights into the
origins of iNPH and demonstrate that it represents a distinct
disease entity.
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Introduction
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological
disorder of aging that is characterized by enlarged cerebral ventri-
cles, gait difficulty, incontinence, and cognitive impairment (Adams
et al, 1965). Because the symptoms can be improved by CSF drai-
nage (Adams et al, 1965; Walchenbach et al, 2002; Wilson &
Williams, 2010), iNPH is classified as a reversible dementia.
According to the Hydrocephalus Association, iNPH affects about
700,000 Americans. It occurs almost exclusively after the age of 60
(the average age at diagnosis is about 75 years). Researchers have
estimated that 1.4–2.9% of the population over the age of 65
(Hiraoka et al, 2008; Jaraj et al, 2014), 5.6% of the population over
the age of 75 (Hiraoka et al, 2008; Martin-Laez et al, 2015), and
nearly 1 in 7 nursing home residents (Marmarou et al, 2007) has
iNPH. Unfortunately, most of these patients are misdiagnosed or
undiagnosed (Marmarou et al, 2007; Hiraoka et al, 2008; Martin-
Laez et al, 2015), in part because the symptoms of iNPH resemble
the symptoms of other neurological disorders such as Parkinson’s
Disease or Alzheimer’s Disease (Jaraj et al, 2014), and in part
because many healthcare providers and the lay public are unfamiliar
with this disorder (Conn & Lobo, 2008). Importantly, not all patients
who present with ventriculomegaly, gait difficulty, incontinence,
and cognitive decline improve after CSF drainage (Relkin et al, 2005;
McGirt et al, 2008), such that a diagnosis of iNPH is only confirmed
if the symptoms improve after CSF drainage and shunt placement
(Relkin et al, 2005; McGirt et al, 2008). This empirical approach to
diagnosis, combined with the similarity to other disorders and the
lack of knowledge about its pathophysiology, has led some practi-
tioners to question whether iNPH exists (Saper, 2017).
Although first described in 1965 (Adams et al, 1965), the etiology
and pathophysiology of iNPH remain a mystery. Ventricular CSF
stasis (Kawaguchi et al, 2011), abnormal cerebrovascular blood flow
and reactivity (Kristensen et al, 1996; Mori et al, 2002), and
increased amplitude of intracranial pressure waves (Eide & Sorte-
berg, 2010) have all been observed in iNPH patients, but the mecha-
nisms underlying these phenomena are unclear. Associations
between iNPH and hypertension, hypercholesterolemia, diabetes,
and alcohol consumption have been reported (Jacobs, 1977; Krauss
et al, 1996; Eide & Pripp, 2014; Hickman et al, 2017), but the physio-
logical mechanisms underlying these associations are not known.
Several reports of familial iNPH have been published, including
pedigrees with autosomal-dominant transmission (Zhang et al,
2008; Takahashi et al, 2011; McGirr & Cusimano, 2012; Huovinen
et al, 2016; Morimoto et al, 2019). One study identified a CFAP43
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mutation as a possible cause of familial iNPH (Morimoto et al,
2019). A recent single-nucleotide polymorphism study reported
intronic copy number loss in the SFMBT1 gene in 26% of sporadic
iNPH patients compared to 4.2% of the general population (Sato
et al, 2016). Another large multinational study of Finnish and
Norwegian iNPH patients used genotyping of SFMBT1 to identify
copy number loss in intron two of SFMBT1 in 10% of Finnish [odds
ratio (OR) = 1.9, P = 0.0078] and 21% of Norwegian (OR = 4.7,
P < 0.0001) patients with iNPH (Korhonen et al, 2018), although
the significance of this finding is yet to be determined. The current




Whole exome sequencing of DNA obtained from 53 patients with
shunt-responsive iNPH was performed in three independent cohorts
(Table 1). Collectively, there were 29 females and 24 males. The
median age was 75 years (range 65–89 years). All of the patients
had enlarged cerebral ventricles and gait difficulty. Urinary inconti-
nence and cognitive impairment were present in 79 and 83% of the
patients, respectively.
Recurrent iNPH-associated deletions
Analysis of sequencing data identified 4 of 53 patients with the same
damaging mutation in CWH43 (Appendix Fig S1). The presence of
the mutation was confirmed in each case by Sanger sequencing
(Fig 1A). The mutation (4:49063892 CA/C; Lys696AsnfsTer23) has
a minor allele frequency (MAF) of 0.0057 in the general population
and 0.0377 among iNPH patients, a 6.6-fold increase (P < 0.0001,
X2 test; P < 0.0002, X2 test with Yates correction). This deletion,
which was heterozygous in each patient and observed in 2 of 3 inde-
pendent cohorts, leads to a frameshift that alters the carboxyl termi-
nus of Cwh43.
Manual examination of sequencing data identified 4 additional
patients harboring a different CWH43 deletion (4:49034669 CA/C;
Leu533Ter) (Appendix Fig S2). This CWH43 deletion generates a
frameshift that causes premature termination of the Cwh43 protein
(Fig 1A). This second deletion was filtered out during the original
analysis because its MAF exceeds 0.01 in the general population.
This CWH43 deletion has a MAF of 0.0142 in the general population
and 0.0377 in our iNPH cohort, and thus occurred with a 2.7-fold
increased frequency (P < 0.0406, X2 test; P < 0.1016, X2 test with
Yates correction). This second CWH43 deletion was also heterozy-
gous in each patient and observed in 2 of 3 independent cohorts.
Taken together, 8 of 53 iNPH patients (15%) carried a recurrent
CWH43 deletion that disrupts the carboxyl terminus of the Cwh43
protein. Each of the eight patients presented with gait difficulty,
incontinence, and cognitive impairment that improved after CSF
drainage. Three of these patients had a family history of iNPH or
gait difficulty, with one patient describing three first degree relatives
who had been diagnosed with iNPH.
Axial T2-weighted MR images of the brain were obtained from
the eight iNPH patients harboring CWH43 deletions and 54
asymptomatic individuals matched for age and gender (www.oasis-
brains.org). The ratio of ventricular to brain cross-sectional area for
each case was obtained. The mean ratio (representing the normal-
ized ventricular size) among the 8 iNPH patients with CWH43 dele-
tions (21.7  1.4) was significantly larger than that of the cohort of
54 asymptomatic age- and gender-matched controls (11.3  0.4;
P < 0.00001, two-tailed t-test; Appendix Fig S3).
Effect of CWH43 deletions on Cwh43 function
Yeast Cwh43 (Cell wall biogenesis protein 43 C-terminal homolog)
is a transmembrane protein that incorporates ceramide into the
glycosylphosphatidylinositol (GPI) anchor that attaches certain
proteins to the cell membrane (Ghugtyal et al, 2007). Incorporation
of ceramide into the lipid anchor of GPI-anchored proteins by
Cwh43 regulates their membrane localization in yeast (Yoko et al,
2018). Although the function of Cwh43 in multicellular organisms is
not known, a lipid-remodeling domain is predicted to reside near
the carboxyl terminus (Fig 1B). The recurrent iNPH-associated
CWH43 mutation (Lys696AsnfsTer23) causes a frameshift that elimi-
nates the last four amino acids of Cwh43 and replaces it with a
novel 23 amino acid sequence. This removes an endoplasmic reticu-
lum (ER) export signal (YF) and adds an ER retrieval signal (KKXX,
Fig 1B) (Matheson et al, 2006). Overexpression of wild-type GFP-
Cwh43 or mutant GFP-Cwh43-k696fs fusion protein in HeLa cells
confirmed that wild-type GFP-Cwh43 is associated with the ER,
intracellular vesicles, and the Golgi apparatus (where modification
of the lipid anchor is thought to occur), while GFP-Cwh43-k696fs is
localized primarily to the ER (Fig 1C).
The other recurrent CWH43 deletion creates a stop codon at
Leu533, thereby generating a truncated Cwh43 protein lacking the
C-terminal ER export signal and the putative lipid-remodeling
domain. Overexpression of human GFP-Cwh43-Leu533Ter in HeLa
cells confirmed that the mutant protein is diffusely distributed
throughout the cytoplasm (Fig 1C).
We generated two independent HeLa cell lines containing a
mutation that truncates the Cwh43 protein at or near Leu533.
Western blot analysis indicated that Cwh43 protein was essentially
undetectable in these cells (Appendix Fig S4). Transient expression
of RFP fused folate receptor alpha and CD59, two GPI-anchored
proteins, showed that loss of Cwh43 expression decreases the
association of GPI-anchored proteins with intracellular vesicles
(Appendix Fig S4). However, flow cytometry indicated that the
amount of CD59 on the surface of CWH43 mutant HeLa cell lines
was not decreased (Appendix Fig S4). Subfractionation of wild-
type and CWH43 mutant HeLa cells into aqueous and lipid
compartments using Triton X-114, followed by Western blot analy-
sis, revealed that the Cwh43 Leu533Ter deletion decreases the
association of CD59 with the lipid microdomain fraction where
GPI-anchored proteins are typically found (Ko & Thompson, 1995)
(Fig 1D), even though the amount of CD59 in the total membrane
fraction increased slightly. The effect of Cwh43 mutation on the
localization of CD59 to the lipid microdomain fraction could be
rescued by overexpression of wild-type GFP-Cwh43, but not
by GFP-Cwh43-k696fs mutant protein (Fig 1D). These findings
suggest that Cwh43 regulates the membrane targeting of GPI-
anchored proteins in human cells. Both of the iNPH-associated
CWH43 deletions disrupt this function.
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Table 1. iNPH patient characteristics.
Cohort Age Sex Sx duration Gait Incontinence Dementia Improvement CWH43 alteration
I 76 F NA ** *** ** ** K669fs
I 79 M NA ** * None *
I 84 F 2 *** ** *** *
I 80 F 2 ** ** *** *
I 80 F 5 *** ** ** *** Leu533Ter
I 68 M NA *** None None **
I 76 F 2 ** * *** *
I 74 M 4 *** * * *** K669fs
I 84 F 2 *** ** None **
I 77 M 6 ** None * *
I 65 F 4 *** *** ** *** K669fs
I 76 F 2 * * * **
I 69 M 2 *** * ** ** Leu533Ter
I 67 M 1 ** ** ** ***
I 76 M NA ** *** ** **
I 77 F 2 *** ** ** **
I 70 F 2 ** ** ** **
I 68 M 3 *** ** ** *** Leu533Ter
I 89 M 10 *** *** ** ***
I 81 M 1 *** *** ** ***
II 75 M 2 * ** * **
II 76 F 2 *** ** ** ***
II 81 F 1 *** *** ** ***
II 81 F 1 *** ** ** **
II 86 M 3 *** ** ** **
II 75 F NA *** ** ** *
II 81 F 1 *** None * *
II 76 M 2 *** ** ** *
II 84 F 3 *** * * * K669fs
II 73 F 4 *** *** ** **
II 70 M 2 ** *** *** *
II 75 F 2 ** ** ** **
III 77 M 20 ** None None **
III 72 F 0.5 ** *** *** *
III 78 M 1 ** * * **
III 73 M NA ** None None **
III 70 F 2 ** * * ***
III 78 M 2 ** None * **
III 75 F 0.5 ** ** * **
III 68 F 3 ** ** * *
III 77 M 3 *** None None **
III 75 M 2 ** None ** **
III 70 F 2 ** ** None ***
III 68 M 2 ** ** ** ***
III 76 M NA *** *** ** ***
ª 2021 The Authors EMBO Molecular Medicine e13249 | 2021 3 of 11
Hong Wei Yang et al EMBO Molecular Medicine
Table 1 (continued)
Cohort Age Sex Sx duration Gait Incontinence Dementia Improvement CWH43 alteration
III 75 F 2 *** ** ** **
III 68 M 1 ** ** ** ** Leu533Ter
III 72 F 1 * * None ***
III 72 F 1 * None None *
III 81 F NA *** ** *** **
III 74 M 2 *** None ** ***
III 79 F 1 *** *** *** ***
III 70 F 0.5 *** * * *
NA, Data not available; None, Symptom not present.
*Mild, **Moderate, and ***Major.
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Figure 1. iNPH-associated deletions disrupt the ability of Cwh43 to regulate the localization of GPI-anchored receptors.
A Sanger DNA sequencing data from two iNPH patients confirming the presence of heterozygous CWH43 deletions. Arrows identify location of the deletion.
B Diagram of the domain structure of the Cwh43 protein illustrating the location of the damaging CWH43 deletions. Lower panel details the disruptive effect of the
k696Asnfs mutation on the C-terminal endoplasmic reticulum export signal (YF), replacing it via a frameshift with a 23 amino acid sequence that contains an
endoplasmic reticulum retention signal (KKKS).
C Fluorescence micrographs of HeLa cells transfected with plasmids encoding human GFP-Cwh43, GFP-Cwh43-k696fs, or GFP-Cwh43-Leu533ter fusion proteins. To label
the ER, HeLa cells were transduced with a baculovirus encoding a fluorescently labeled RFP-calreticulin fusion protein containing an ER retention signal (RFP-
calreticulin-KDEL). To label the Golgi apparatus, cells were immunostained for golgin-97 (red). When compared with wild-type GFP-Cwh43, GFP-Cwh43-k696fs, and
GFP-Cwh43-Leu533 showed decreased association with the Golgi apparatus (but not the ER) and were diffusely distributed throughout the cytoplasm. Scale bar is
approximately 5 µm.
D Western blot analysis of total membrane, aqueous and lipid (GPI-anchor-containing) Triton X-114 extracts derived from wild-type HeLa cells, and two independent
CRISPR CWH43 knockout (KO) HeLa cell lines in which a mutated CWH43 gene encodes a protein that is truncated near Leu533 and CWH43 mRNA and protein are
markedly reduced. Cells were transfected to overexpress a control GFP plasmid, a plasmid encoding human wild-type Cwh43 with GFP fused to the N-terminus, or a
plasmid encoding human CWH43 harboring the iNPH-associated mutation (Lys696AsnfsTer23) with GFP fused to the N-terminus. The Western blot was stained using
an antibody directed against CD59, a GPI-anchored protein.
Source data are available online for this figure.
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Cwh43 expression in the mouse brain
Mouse mRNA in situ hybridization images (Lein et al, 2007)
revealed increased Cwh43 mRNA expression in the choroid plexus,
layer CA1-CA3 of the hippocampus, several thalamic nuclei, and
layer V of the cerebral cortex (Fig 2A). Using frozen cryostat
sections of the mouse brain, we found that Cwh43 immunoreactiv-
ity was concentrated in the ventricular ependymal layer (Fig 2B)
and choroid plexus (Appendix Fig S5). In cultured mouse ependy-
mal cells, Cwh43 immunoreactivity was observed in the soma and
in motile cilia (Fig 2C).
Effect of Cwh43 deletion in mice
Using CRISPR/Cas9 technology, we generated two independent lines
of CWH43 mutant mice (Appendix Fig S6). CWH43M533 mice harbor
a mutation (Met533Ter) corresponding to human 4:49034669 CA/C;
Leu533Ter. We generated a second mouse line (CWH43M533/A530)
harboring one CWH43M533 allele and a CWH43 allele that results in
termination of Cwh43 at A530, three amino acids before Met533.
Heterozygous CWH43WT/M533, homozygous CWH43M533/M533, and
compound heterozygous CWH43M533/A530 mice appeared grossly
normal and were fertile.
We used MRI to assess ventricular volume in the brains of 6-
month-old wild-type and CWH43 mutant mice (Fig 3A and B).
When compared to CWH43WT/WT mice, ventricular volume was
increased by approximately 24.2% in CWH43WT/M533 heterozygous
mice (P < 0.0015, n = 8, unpaired t-test), 18.3% in CWH43M533/M533
homozygous mice (P < 0.0014, n = 5, unpaired t-test), and 20.8%
in CWH43M533/A530 compound heterozygous mice (P < 0.0064,
n = 8, unpaired t-test). Light microscopy indicated that the brains of
CWH43 mutant mice were grossly normal and the cerebral aqueduct
was patent. Injection of fluorescent dextran (70 kDa) into the lateral
ventricle resulted in filling of the fourth ventricle with dextran
within 10 min, confirming that this was a communicating hydro-
cephalus (Appendix Fig S7). Immunohistochemistry for Cwh43
revealed a loss of Cwh43 immunoreactivity in the ventricular epithe-









Ac-Tubulin Cwh43 DAPI Merge
Figure 2. Expression of Cwh43 mRNA and protein in the mouse brain.
A mRNA in situ hybridization images showing expression of Cwh43 mRNA in the mouse brain. Enclosed areas containing potions of the ventricle, hippocampus, and
dorsal thalamus are shown at higher magnification on the right. Arrowheads point to choroid plexus. Scale bar is approximately 400 µm.
B Fluorescence immunohistochemistry of the ependymal surface of the lateral ventricle of the mouse brain. Cilia are visualized using an antibody for acetylated alpha
tubulin (green). Cwh43 is visualized using a specific anti-Cwh43 antibody (red). Nuclei are counterstained using DAPI (blue). Arrowheads point to motile cilia and
scale bar is approximately 5 µm.
C Confocal fluorescence immunocytochemistry images of a single cultured mouse ciliated ependymal cell. Cilia were visualized using an antibody for acetylated alpha
tubulin (green). Cwh43 immunoreactivity was visualized using a specific anti-Cwh43 antibody (red). Scale bar (left column) is approximately 4 µm. Images in the
column on the right represent a Z-stack reconstruction of confocal images showing localization of Cwh43 immunoreactivity in cilia of a mouse ependymal cell. Scale
bar (right column) is approximately 5 µm.
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Quantitative gait analysis in CWH43 mutant mice at 7 months
revealed increased rear leg sway (Fig 3C, P < 0.011, n = 9, unpaired
t-test) when compared to wild-type mice. Using the rotarod perfor-
mance test to evaluate balance and coordination, we observed
significantly decreased balance times for CWH43WT/M533 heterozy-
gous mice (P < 0.0405, n = 8, unpaired t-test), CWH43M533/M533
homozygous mice (P < 0.0323, n = 7, unpaired t-test), and
CWH43M533/A530 compound heterozygous mice (P < 0.03, n = 4,
unpaired t-test) when compared to wild-type mice (Fig 3D).
Electron microscopy examination of the mouse brain ventricular
surface revealed a decrease in the number of ependymal cilia by
approximately 28% in CWH43M533/M533 homozygous mice (P <
0.0037, n = 4, unpaired t-test, Fig 4A) and 25% in CWH43M533/A530
compound heterozygous mice (P < 0.0003, n = 6, unpaired t-test,
Appendix Fig S9) when compared to wild-type mice. The number
of microvilli on the ependymal surface also appeared to be
decreased in CWH43 mutant mice. Obvious differences in cilia
length were not observed. Immunohistochemistry confirmed
the decrease in ependymal cilia in CWH43M533/A530 mice
(Appendix Fig S9).
We used Triton X-114 to subfractionate brain and kidney tissues
from CWH43WT/WT, CWH43WT/M533, and CWH43M533/M533 mice into
aqueous and lipid compartments. Western blot analysis revealed
that CWH43 mutation decreases the association of the GPI-anchored
protein, CD59, with the lipid microdomain fraction in heterozygous
CWH43WT/M533 and homozygous CWH43M533/M533 mice in vivo
(Fig 4B). Immunohistochemistry revealed that CWH43 mutation















































































Figure 3. CWH43 mutation increases ventricular volume and causes gait dysfunction in mice.
A Scatter plot comparing ventricular volume from CWH43WT/WT (wild-type, WT), heterozygous CWH43WT/M533, homozygous CWH43M533/M533, and CWH43M533/A530 mice
at 6 months. Ventricular volume was calculated from T2-weighted MR images of the mouse brain using a custom automated computer algorithm. Horizontal bars
indicate the mean of the measurements in each column. Statistical significance for each mutant mouse line compared to WT was determined using the unpaired
t-test (P = 0.0015 for CWH43WT/M533; P = 0.0014 for CWH43M533/M533; P = 0.006 for CWH43M533/A530).
B Representative 3D volumetric MR images of mouse brains from 6-month-old CWH43WT/WT, CWH43M533/M533, and CWH43M533/A530 mice. LV = lateral ventricle, 3rd
V = third ventricle, 4th V = fourth ventricle. Scale bar is approximately 1 mm.
C Quantitative gait analysis at 7 months of age revealed increased sway among homozygous CWH43M533/M533 mice, (*P = 0.03, n = 5) and compound heterozygous
CWH43M533/A530 (*P = 0.034, n = 4) mice when compared to wild-type CWH43WT/WT mice (n = 5). Sway (the distance between the hind paws during walking) was
measured repeatedly for individual mice in each group during a constrained unidirectional walk. Data shown are the mean  SD for each group. Statistical
significance was determined using the unpaired t-test.
D Box plot showing rotarod performance data for CWH43WT/WT, CWH43WT/M533, CWH43M533/M533, and CWH43M533/A530 mice at 7 months of age. Data shown are the
mean, 1st quartile, 3rd quartile, minimum, and maximum for each group of mice. Statistical significance was determined using the unpaired t-test. When compared to
wild-type CWH43WT/WT mice (n = 10), balance time on the rotarod was decreased significantly among heterozygous CWH43WT/M533 mice (*P = 0.04, n = 8),
homozygous CWH43M533/M533 mice (*P = 0.03, n = 7), and compound heterozygous CWH43M533/A530 mice (*P = 0.03, n = 4).
Source data are available online for this figure.
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basal membrane of multiciliated choroid plexus and ependymal
cells in CWH43M533/M533 and CWH43M533/A530 mice (Fig 4C).
Discussion
As the US population ages, iNPH has become a growing (albeit
underappreciated) public health problem. iNPH patients often suffer
from an inability to walk unassisted, frequent falls, urinary or fecal
incontinence, and cognitive impairments that prevent them from
living independently (Adams et al, 1965; McGirt et al, 2005; Graff-
Radford, 2007). Nearly 6% of individuals will develop this disorder
by the age of 75 (Hiraoka et al, 2008; Tanaka et al, 2009; Martin-
Laez et al, 2015), and estimates suggest that 14% of nursing home
residents have iNPH (Marmarou et al, 2007). Thus, our finding that
iNPH-associated CWH43 deletions occur in approximately 3% of the
general population is in keeping with current prevalence estimates
of iNPH (Marmarou et al, 2007; Tanaka et al, 2009; Martin-Laez
et al, 2015). Although each of the three cohorts in our study was
limited in size, we nevertheless observed that CWH43 deletions
were overrepresented in each one. Importantly, CWH43 deletions
accounted for only 15% of iNPH patients in our cohort, suggesting
that other genetic or environmental factors (Sato et al, 2016;
Hickman et al, 2017) contribute to the development of iNPH.
Most iNPH patients do not report a family history of the disease
(Huovinen et al, 2016), but autosomal-dominant transmission has
been reported (Zhang et al, 2008; Takahashi et al, 2011; McGirr &
Cusimano, 2012; Morimoto et al, 2019). Although a family history
of iNPH was not required for entry into this study, three of eight
patients with CWH43 deletions reported a family history of iNPH or
gait difficulty. Importantly, we observed that humans and mice
heterozygous for iNPH-associated CWH43 deletions display an
increase in ventricular volume as well as gait and balance dysfunc-
tion, consistent with an autosomal-dominant pattern of inheritance.
Although iNPH patients appear functionally normal at birth and
only develop symptoms after the sixth decade of life, they can
develop progressive ventriculomegaly prior to symptom onset
(Engel et al, 2018). Likewise, CWH43 mutant mice appear normal at
birth and show no major deficits through middle age. However,
careful testing revealed enlarged ventricles and gait dysfunction
during this period. This animal model of iNPH thus accurately

























































Figure 4. CWH43 mutation decreases cilia number and alters the distribution of GPI-anchored proteins in mouse ventricular ciliated epithelia.
A Scanning electron micrographs of the ependymal surface of the lateral ventricle of CWH43 WT and CWH43M533/M533 mice. Scale bar is approximately 40 µm. The
graph on the right quantifies the data from the electron micrographs on the left. Data shown are the mean  SEM. *P = 0.004, n = 4, unpaired t-test.
B Western blot analysis of total membrane, aqueous, and lipid (GPI-anchor-containing) Triton X-114 extracts derived from wild-type, CWH43M533/M533, and CWH43WT/
M533 mouse brain or kidney. The Western blot was stained using an antibody directed against CD59, a GPI-anchored protein.
C Fluorescence immunohistochemistry for CD59 in the ependymal layer and choroid plexus of the lateral ventricle from CWH43WT/WT, CWH43M533/M533, and CWH43M533/
A530 mice. Arrowheads point to apical surfaces of ependymal and choroid plexus cells. Nuclei are counterstained using DAPI (blue). Scale bar is approximately 5 µm.
Source data are available online for this figure.
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Mutations affecting proteins involved in GPI-anchored protein
synthesis can cause mental retardation, microcephaly, and seizures,
while complete disruption of GPI-anchored protein synthesis is
lethal (Kinoshita, 2014). Although Cwh43 modifies the lipid anchor
of certain GPI-anchored proteins, it is not required for their basic
synthesis. This fact may help to explain the absence of symptoms
until late in life in iNPH patients.
In yeast, the incorporation of ceramide into the lipid anchor of
GPI-anchored proteins by Cwh43 promotes the retention of these
proteins on the plasma membrane (Yoko et al, 2018). Loss of
Cwh43 function in yeast leads to aberrant expression of these
proteins on the cell wall. The Golgi apparatus is thought to be a
primary site where the lipid anchor of GPI-anchored proteins is
modified and where GPI-anchored proteins are incorporated into
vesicles for transport to their final destination on the cell membrane
(Matheson et al, 2006). We observed strong expression of Cwh43 in
the Golgi apparatus of mammalian cells. However, both of the
iNPH-associated CWH43 deletions cause a loss of Cwh43 protein in
the Golgi apparatus and disrupt the targeting of certain GPI-
anchored proteins (e.g., CD59) to lipid microdomains in the plasma
membrane and to the apical membrane of polarized ventricular
epithelial cells. Our data thus provide the first evidence that Cwh43
regulates the subcellular targeting of GPI-anchored proteins in
mammalian cells. We hypothesize that mislocalization of GPI-
anchored proteins in choroid plexus and ependymal epithelial
cells harboring mutant Cwh43 disrupts the normal function of
these cells.
A decline in the number of ciliated ventricular cells has been
observed in aged asymptomatic individuals with enlarged ventri-
cles and in patients with chronic hydrocephalus (Del Bigio, 1993;
Shook et al, 2014). Published reports regarding genetic causes of
hydrocephalus in humans and in mice, as well as numerous
experimental studies of induced hydrocephalus, have implicated
loss or dysfunction of ventricular multiciliated epithelia in the
etiology of many forms of hydrocephalus (Del Bigio, 1993; Huh
et al, 2009; Shook et al, 2014; Narita & Takeda, 2015; Kahle et al,
2016; Morimoto et al, 2019). Our finding that CWH43 mutations
affect ependymal cilia number and apical/basal targeting of GPI-
anchored proteins in ventricular multiciliated epithelial cells
suggests that dysfunction of these cells may contribute to the
development of iNPH. We propose a model in which decreased
Cwh43 function disrupts the trafficking of GPI-anchored proteins
and leads to a decrease in the function and/or number of ventricu-
lar multiciliated cells and ventricular enlargement. This combines
with age-related declines in cell number to produce an age-depen-
dent compromise of ventricular multiciliated cell function, ventric-
ular enlargement, and iNPH onset at an advanced age. Further
studies will examine whether CWH43 mutations lead to hydro-
cephalus via additional mechanisms.
Many practitioners are unfamiliar with iNPH (Conn & Lobo,
2008), and some even question whether iNPH exists as a sepa-
rate disease entity (Saper, 2017). This skepticism and lack of
familiarity contribute to the low rates of diagnosis and treatment
of this disorder. Our finding that loss of function CWH43 dele-
tions are enriched among iNPH patients and produce an iNPH-
like syndrome in mice provides key mechanistic insights into




Fifty-three unrelated patients who presented to a neurosurgical clinic
with unexplained complaints of ventricular enlargement, gait difficulty,
incontinence, and/or cognitive decline underwent an evaluation that
included a history, neurological examination, and cranial imaging.
Patients were consented for the study prior to CSF drainage. The experi-
ments conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services Belmont
Report. A trial of lumbar CSF drainage was then performed. Quantita-
tive measurements of gait speed, stride length, and performance on the
Timed Up and Go (TUG) test, as well as patient and caregiver reports of
changes in urinary incontinence, were used to assess symptoms before
and after CSF drainage as we have described previously (Yang et al,
2016). Only those patients who improved after a trial of CSF drainage
and subsequent ventriculoperitoneal shunt placement were included
for whole exome analysis.
Whole exome sequencing and data analysis
The 53 patients with shunt-responsive iNPH were enrolled and
analyzed in three separate cohorts (n = 20, n = 12, and n = 21).
Genomic DNA was isolated from whole blood and submitted for whole
exome sequencing (50× coverage, 150 bp paired-end sequencing, Illu-
mina HiSeq 2000). Single-nucleotide variants (SNVs) and insertions/
deletions (indels) were identified (Human Genome build GRCh37, bwa-
mem, Genome Analysis Toolkit HaplotypeCaller). Genetic alterations
with a frequency greater than 1% in the 1000 Genomes Project data-
base (1000 Genomes Project, National Human Genome Research Insti-
tute, www.1000genomes.org) or the ExAC database (Huh et al, 2009;
Karczewski et al, 2017) were initially excluded. The minor allele
frequency (MAF) of each mutation in the study group was compared to
that in the general population (combined MAF across all ethnic groups,
ExAC database), and statistical enrichment among iNPH patients was
calculated using the two-tailed chi-square test with and without the
Yates correction. Four publicly available computer prediction algo-
rithms (SIFT, Provean, Mutation Tester, and Polyphen 2) were used to
predict the effect of each mutation on protein function. Genes with
three or more mutations that were predicted to be damaging by at least
two of the four computer prediction algorithms were selected for
further study. Further examination of CWH43, a gene that harbored the
most recurrent damaging mutation, revealed another recurrent damag-
ing deletion with a MAF of 0.0142 in the general population. This dele-
tion resulted in a frameshift and truncation of the encoded protein and
was thus included in the study. Genetic alterations were confirmed
using polymerase chain reaction (PCR) and Sanger sequencing.
Immunohistochemical staining
In situ mRNA hybridization images for CWH43 were obtained from
a public database (Allen Brain Atlas; Lein et al, 2007; Kahle et al,
2016). Cryostat sections of mouse brains were prepared and stained
for fluorescence immunohistochemistry using antibodies directed
against Cwh43 (1:500, Sigma, Human Protein Atlas HPA042814),
CD59 (1:200, Santa Cruz, clone H-7), ZO-1 (1:250, Thermo Fisher,
339194), or acetylated a-tubulin (1:500, Cell Signaling, 5335S).
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Nuclei were counterstained using 40,6-diamidino-2-phenylindole
(DAPI).
Ventricular ependymal cells from newborn wild-type mice were
dissociated and cultured in medium containing 2% serum. The cells
were then fixed in paraformaldehyde, stained using antibodies
against Cwh43 and acetylated a-tubulin (to visualize cilia), and
imaged using fluorescence confocal microscopy.
Functional analysis of Cwh43 in vitro
Human HeLa cells harboring the CWH43 (4:49034669 CA/C;
Leu533Ter) were generated using the CRISPR/Cas9 method. The
mutation was confirmed by DNA sequencing, and loss of Cwh43
protein expression was confirmed by Western blot. Expression plas-
mids for wild-type human CWH43 and human CWH43 harboring
either the iNPH-associated deletion (4:49063892 CA/C; Lys696Asnf-
sTer23) or (4:49034669 CA/C; Leu533Ter) were generated using
site-specific mutagenesis. Expression plasmids encoding Green Fluo-
rescent Protein (GFP) fused to the N-terminus of these CWH43 vari-
ants were also generated. HeLa cell lines stably expressing each
fusion protein were then generated by transient transfection
followed by antibiotic selection. Expression plasmids encoding RFP-
CD59 or RFP-Folate receptor alpha were generated and overex-
pressed in HeLa cells via transient transfection. To label the
endoplasmic reticulum (ER), a baculovirus encoding RFP-calreticulin-
KDEL (Thermo Fisher, Cell Light BacMam 2.0) was used. To label
the Golgi apparatus, HeLa cells were fixed in paraformaldehyde and
immunostained using an anti-golgin-97 antibody (Cell Signaling,
clone D8P2K). Cell surface CD59 in HeLa cells was detected by flow
cytometry using a CD59-FITC antibody (BD Pharmingen, 556640).
Generation and analysis of CWH43 mutant mice
C57bl6 mice harboring a Met533Ter mutation (coinciding to the
human CWH43 deletion 4:49034669 CA/C; Leu533Ter) were gener-
ated using CRISPR/Cas9 and bred to generate heterozygous
(CWH43WT/M533) and homozygous (CWH43M533/M533) animals. To
control for CRISPR/Cas9 off-target effects, we independently gener-
ated a second C57bl6 mouse line harboring one mutant Met533Ter
allele and one allele containing a 10 bp deletion (ACCAGCCATA) in
CWH43 that generates a stop codon at A530 (CWH43M533/A530). Both
CWH43 mutant mouse lines were studied for comparison.
Axial T2-weighted magnetic resonance (MR) brain images from 8
iNPH patients harboring CWH43 deletions were obtained from medi-
cal records. Axial T2-weighted MR brain images from 54 age- and
gender-matched asymptomatic individuals were obtained from a
publicly available database (www.oasis-brains.org; OASIS-3: Longi-
tudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal
Aging and Alzheimer’s Disease). Using NIH Image J software, the
cross-sectional areas of the brain and ventricles at a level just above
the interthalamic adhesion were measured. The ratio of ventricular
area to brain area was obtained for each case. Ratios from iNPH
patients harboring CWH43 deletions were then compared to those
from asymptomatic controls. Statistical significance was calculated
using the two-tailed t-test.
T2-weighted MR images of the brains of CWH43 mutant mice
were obtained, and ventricular volume was calculated using Image
J and a custom automated computer algorithm. In some cases,
mouse brains were harvested and the ventricular surface was fixed
for examination using immunohistochemistry or scanning electron
microscopy. Color-coded spatial analysis of gait in mice was
performed using a placemat and quantitative measurement of stride
length, stance, and sway. Evaluation of strength, balance, and coor-
dination in mice was performed using the rotarod performance test.
Statistical significance for laboratory studies was calculated using
the two-tailed unpaired t-test with a significance threshold of
P < 0.05.
Statistical analysis
Genetic alterations of greater than 1% in publicly available data-
bases (1000 Genomes Project database, National Human Genome
Research Institute, www.1000genomes.org or the ExAC database)
were initially excluded. The minor allele frequency (MAF) of each
mutation in the study group was compared to that in the general
population (combined MAF across all ethnic groups, ExAC data-
base), and statistical enrichment among iNPH patients was calcu-
lated using the two-tailed chi-square test with and without the Yates
correction. Animals were grouped based on their genotype, mean
and standard deviation were calculated for each group, and the
appropriate t-test was used to determine the statistical significance.
The paper explained
Problem
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological
disorder of aging that is characterized by enlarged cerebral ventricles,
gait difficulty, incontinence, and cognitive decline. The cause and
pathophysiology of iNPH are unknown. Although iNPH affects an esti-
mated 700,000 Americans, most remain undiagnosed because many
practitioners are unfamiliar with the disease or doubt its existence.
Results
We performed whole exome sequencing of DNA obtained from 53
unrelated iNPH patients. Damaging SNVs and indels affecting the
most frequently altered gene were studied further using genetically
engineered mice and human cell lines. A heterozygous damaging dele-
tion in CWH43 was observed in four iNPH patients and was enriched
6.6-fold among iNPH patients when compared to the general popula-
tion (P < 0.0002, X2 test). A second heterozygous damaging CWH43
deletion was identified in four additional patients and was enriched
2.7-fold. We found that Cwh43 regulates the membrane localization
of GPI-anchored proteins in mammalian cells, and both of the iNPH-
associated CWH43 deletions disrupt this function. In the mouse brain,
Cwh43 expression is high in ciliated ependymal and choroid plexus
cells. Mice heterozygous for CWH43 deletions appeared grossly normal
but displayed enlarged ventricles, gait and balance abnormalities,
decreased numbers of ependymal cilia, and decreased localization of
GPI-anchored proteins to the apical surfaces of choroid plexus and
ependymal cells.
Impact
Approximately 15% of patients with iNPH harbor heterozygous loss of
function deletions in CWH43. Mice harboring iNPH-associated CWH43
deletions develop communicating hydrocephalus, gait dysfunction,
and choroid plexus and ependymal cell abnormalities. Our findings
provide novel mechanistic insights into the origins of iNPH and
demonstrate that it represents a distinct disease entity.
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Data availability
The whole exome sequencing data from normal pressure hydro-
cephalus patients are available in dbGaP https://www.ncbi.nlm.nih.
gov/projects/gapprev/gap/cgi-bin/study.cgi?study_id=phs002296.v1.
p1). The accession ID is phs002296.v1.p1.
Expanded View for this article is available online.
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